Isomorphic Labs and Full-Life Technologies raise multibillion and hundred‑million dollars for AI‑driven drugs and radiol

Isomorphic Labs, a British AI drug‑design company co‑founded by Demis Hassabis, announced a $2.1 billion Series B financing round led by Thrive Capital. Existing backers Alphabet and GV, along with new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund, took part. The capital will be used to expand the company’s AI engine, scale global operations and push its pipeline of therapeutic candidates toward clinical testing.

Full-Life Technologies completed a $150 million financing package—about $110 million in Series D equity and $40 million in debt—led by Vivo Capital and joined by SK Biopharmaceuticals and several other investors. The proceeds will advance its clinical‑stage actinium‑225 radiotherapeutics for prostate cancer and solid‑tumour indications and fund a GMP‑grade manufacturing facility in Belgium.